$DVAX Dear Axeljohntrees. Yes, you are correct about $50 million revenue in 2020. In 2021 projection is $120 million just in the US alone. Later this year DVAX will probably submit NDA for HEPLISAV B treatment for Hemodialysis patients, which are Big revenue generator. Then probably will add HEPLISAV B prophylactic vaccines for diabetics population which accounts for 31 million of Americans. Then when you add US MILITARY, DOD MILITARY, FOREIGN MILLITARY...NUMBERS JUST BECOME Exponential. Please don’t repeat old news from 2020. Stars are aligned for DVAX revenue to grow exponentially over the next decade.